• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Abdominal Neoplasms

Abdominal Neoplasms - 350 Studies Found

Completed : Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
:
  • Ovarian Neoplasm
  • Fallopian Tube Cancer
  • Primary Peritoneal
    : 2007-02-15
    :
    • Drug: Bevacizumab bevacizumab

Completed : Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
:
  • Ovarian Cancer
  • Primary Peritoneal Cavity Cancer

: 2006-12-06
:
  • Biological: carcinoembryonic antigen-expressing measles virus

Terminated : Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer
:
  • Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer : 2006-12-05
    :
    • Drug: Bevacizumab cycle 2 (6 c

Terminated : ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
:
  • Fallopian Tube Neoplasms
  • Peritoneal Neoplasms
  • Ovarian Neop
    : 2006-12-01
    :
    • Drug: ABI-007 80mg/m^2 to 150m

Completed : Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
:
  • Leukemia
  • Lung Cancer
  • Malignant Mesothelioma
  • : 2006-11-09
    :
    • Biological: WT-1 analog peptide vaccine
    • Bi

Completed : Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")
:
  • Ovarian Cancer
  • Fallopian Tube Neoplasms
  • Peritoneal Neoplas
    : 2006-10-19
    :
    • Drug: enzastaurin 1125 mg load

Completed : Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
:
  • Recurrent Fallopian Tube Cancer
  • Recurrent Ovarian Epithelial Cancer
  • Drug: sunitinib malate Given P

Completed : OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
:
  • Fallopian Tube Cancer
  • Peritoneal Neoplasms
  • Ovarian Cancer<
    : 2006-09-28
    :
    • Drug: phenoxodiol 400mg phenox

Terminated : Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
:
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Primary Peritoneal Ca
    : 2006-09-06
    :
    • Biological: MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine

Withdrawn : Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
:
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Peritoneal Cavity Can
    : 2006-08-29
    :
    • Drug: carboplatin
    • Drug: gemcitabine hydroc

<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.